UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial

BMC cancer, 2020-02, Vol.20 (1), p.122-8, Article 122

2020

Link zum Volltext

Verfügbarkeit prüfen

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

The Lancet (British edition), 2023-10, Vol.402 (10409), p.1272-1281

2023

Link zum Volltext

Verfügbarkeit prüfen

The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI

BMC cancer, 2017-12, Vol.17 (1), p.893-893, Article 893

2017

Link zum Volltext

Verfügbarkeit prüfen

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO

European journal of cancer (1990), 2022-04, Vol.165, p.48-57

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy

International journal of cancer, 2024-06, Vol.154 (12), p.2142-2150

2024

Link zum Volltext

Verfügbarkeit prüfen

Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM

International journal of cancer, 2023-07, Vol.153 (1), p.153-163

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2‐Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

The oncologist (Dayton, Ohio), 2020-08, Vol.25 (8), p.e1181-e1187

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

Nature communications, 2023-08, Vol.14 (1), p.5032-5032, Article 5032

2023

Link zum Volltext

Verfügbarkeit prüfen

Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?

American Society of Clinical Oncology educational book, 2019-01, Vol.39 (39), p.e88-e95

2019

Link zum Volltext

Verfügbarkeit prüfen

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

The Lancet (British edition), 2019-05, Vol.393 (10184), p.1948-1957

2019

Link zum Volltext

Verfügbarkeit prüfen

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

The lancet oncology, 2016-12, Vol.17 (12), p.1697-1708

2016

Link zum Volltext

Verfügbarkeit prüfen

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma

BMC cancer, 2018-04, Vol.18 (1), p.442-9, Article 442

2018

Link zum Volltext

Verfügbarkeit prüfen

First Clinical Data of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as Salvage Therapy for Peritoneal Metastatic Biliary Tract Cancer

Anticancer research, 2018-01, Vol.38 (1), p.373-378

2018

Link zum Volltext

Verfügbarkeit prüfen

Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO

BMC cancer, 2021-10, Vol.21 (1), p.1158-9, Article 1158

2021

Link zum Volltext

Verfügbarkeit prüfen

RAMIRIS: Wirksamkeit von Ramucirumab plus FOLFIRI vs. Ramucirumab plus Paclitaxel bei Patienten mit fortgeschrittenem oder metastasiertem Adenokarzinom des Magens oder des gastroösophagealen Übergangs, die auf eine Erstlinientherapie progredient sind – eine randomisierte Phase-II/III-Studie der AIO

Forum (Heidelberg), 2020-06, Vol.35 (3), p.249-251

2020

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC - the AIO/ CALGP/ ACO- GAIN-trial

BMC cancer, 2020-02, Vol.20 (1)

2020

Link zum Volltext

Verfügbarkeit prüfen

GAIN: Neoadjuvante Chemotherapie mit Gemcitabin plus Cisplatin, gefolgt von radikaler Leberresektion versus direkter radikaler Leberresektion mit oder ohne adjuvante Chemotherapie bei zufällig nachgewiesenem Gallenblasenkarzinom nach einfacher Cholezystektomie oder vor radikaler Resektion eines BTC (ICC oder ECC)

Forum (Heidelberg), 2020-06, Vol.35 (3), p.252-254

Götze, Thorsten O.

2020

Link zum Volltext

Verfügbarkeit prüfen

ADJUBIL: Immuntherapie mit Durvalumab und Tremelimumab in Kombination mit oder ohne Capecitabin im adjuvanten Setting für maligne biliäre Tumoren – eine Phase-II-Studie

Forum (Heidelberg), 2021-10, Vol.36 (5), p.414-416

2021

Link zum Volltext

Verfügbarkeit prüfen

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo naïve upper gi-adenocarcinomas with peritoneal seeding – a phase II/III trial of the AIO/CAOGI/ACO

Pleura and peritoneum, 2018-06, Vol.3 (2), p.20180113-20180113

2018

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to “Dissecting the genetic heterogeneity of gastric cancer”

EBioMedicine, 2023-08, Vol.94, p.104709-104709, Article 104709

2023

Link zum Volltext

Verfügbarkeit prüfen

Constitutive Expression and Regulation of Rat Complement Factor H in Primary Cultures of Hepatocytes, Kupffer Cells, and Two Hepatoma Cell Lines

Laboratory investigation, 2002-02, Vol.82 (2), p.183-192

2002

Link zum Volltext

Verfügbarkeit prüfen

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(24)

Sprache

Englisch
(21)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

Oncology
(17)
Science & Technology
(15)
Life Sciences & Biomedicine
(14)
Humans
(10)
Chemotherapy
(9)
Adenocarcinoma - Drug Therapy
(7)
Adenocarcinoma - Pathology
(7)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(7)
Metastasis
(7)
Stomach Neoplasms - Pathology
(7)
Cancer
(6)
Stomach Neoplasms - Drug Therapy
(6)
Surgery
(6)
Tumors
(6)
Adenocarcinoma
(5)
Cancer Therapies
(5)
Care And Treatment
(5)
Cisplatin
(5)
Medical Prognosis
(5)
Adenocarcinoma - Surgery
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO

FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group

Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy

Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial

Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM

Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2‐Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma

First Clinical Data of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as Salvage Therapy for Peritoneal Metastatic Biliary Tract Cancer

Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO

ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer-The Randomized Multicenter Phase II NEPAFOX Trial

ADJUBIL: Immuntherapie mit Durvalumab und Tremelimumab in Kombination mit oder ohne Capecitabin im adjuvanten Setting für maligne biliäre Tumoren – eine Phase-II-Studie

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo naïve upper gi-adenocarcinomas with peritoneal seeding – a phase II/III trial of the AIO/CAOGI/ACO

Corrigendum to “Dissecting the genetic heterogeneity of gastric cancer”

Constitutive Expression and Regulation of Rat Complement Factor H in Primary Cultures of Hepatocytes, Kupffer Cells, and Two Hepatoma Cell Lines

Suchergebnisse filtern